NASDAQ-listed AGAPE ATP Corporation (ATPC) has announced a strategic collaboration with FORMEDIC Technologies Sdn. Bhd. to introduce LEGA, an electronic chest percussion device designed for respiratory care. This partnership aims to address the increasing demand for advanced respiratory solutions, marking a significant advancement in the field of respiratory health.
LEGA, FORMEDIC’s flagship product, provides essential support for patients suffering from chronic obstructive pulmonary diseases (COPD), pneumonia, bronchiectasis, and other lung-related conditions. The device aids in airway clearance and secretion management, offering vital relief to both adults and children experiencing respiratory difficulties in hospital and home care settings. With nearly 2,000 units already deployed in major hospitals and rehabilitation centres across Malaysia and globally, LEGA has made a considerable impact in the medical community.
This collaboration opens up new opportunities for ATPC in the rapidly expanding respiratory care market, projected to reach USD 25.95 billion in 2024 and estimated to grow to USD 49.84 billion by 2031. As respiratory diseases continue to rise worldwide, the partnership positions ATPC to capitalise on the growing demand for advanced respiratory solutions while diversifying its wellness portfolio with a proven medical device.
Prof Dato’ Sri Dr How Kok Choong, the Founder and Global Group CEO of ATPC, remarked, “The partnership allows ATPC to leverage FORMEDIC’s expertise in healthcare technology and clinical applications, aligning with ATPC’s long-term vision of building a holistic wellness ecosystem that encompasses both preventive and curative solutions. This is an opportunity for us to address a critical global health need. With LEGA, we are expanding our operations into healthcare technology, an area with immense growth potential. We look forward to continuing to deliver value through innovation and strategic diversification while accelerating ATPC’s growth and market reach, enhancing shareholder value.”
Ng Zim Guan, Director of FORMEDIC Technologies, added, “LEGA is the culmination of years of research and clinical trials, and our partnership with ATPC allows us to reach more patients globally. We aim to redefine respiratory care with cutting-edge solutions, and LEGA’s non-invasive, electronic chest percussion technology has already proven to be a vital tool in improving respiratory health. Partnering with ATPC allows us to further scale this technology and reach more patients in need.”
Beyond enhancing lung health, the collaboration will focus on ongoing research and development efforts to explore innovations and improve patient outcomes. Both ATPC and FORMEDIC will work together to develop marketing strategies to position LEGA as the leading respiratory care solution, ensuring greater accessibility for hospitals, rehabilitation centres, and home users worldwide.
